Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (26516)	11/16/1998 12:53:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Ligand is asking for approval as a primary treatment to be used 2-4 times daily. Panel said that it would not recommend Panretin as a "first-line treatment" Ligand did disagree with FDA reviewers on the extent of the response and that they classified many of patients that the FDA considered as "non-responders" as responders. Some of the patients that the FDA thought were non-responders, were considered responders by the patients themselves. Ligand also took exception to using pictures to evaluate what was a "response", becasue of lack of standardization.